NASH 10/2017 Pharmacologic Inhibition of FASN Reverses Diet-Induced Steatohepatitis in Mice and Inhibits Lipogenesis in Humans. AASLD Graviton Love6
NASH 04/2017 Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH EASL International Liver Congress Graviton Love6
Oncology 12/2016 Heavily Pre-Treated Breast Cancer Patients show Promising Responses in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 in Combination with Paclitaxel San Antonio Breast Cancer Symposium Graviton Love6
NASH 11/2016 Pharmacological inhibition of FASN Prevents High Fat Diet Induced Liver Damage in Mice and Significantly Reduces de novo Lipogenesis in Humans AASLD The Liver Meeting Graviton Love6
Oncology 11/2016 Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase Inhibitor, TVB-2640 NCRI Cancer Conference Graviton Love4
Oncology 06/2016 Preliminary Activity in the First in Human Study of the First-In-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 ASCO Annual Meeting Graviton Love4
Oncology 04/2016 FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study AACR Annual Meeting Graviton Love4
Oncology 04/2016 Preclinical studies characterize tumor type sensitivity to FASN inhibition and the mechanism and efficacy of novel drug combinations with TVB-2640 AACR Annual Meeting Graviton Love4
Oncology 02/2016 Sebum Analysis from Dose Escalation and Expansion Phases of the FASN Inhibitor TVB-2640 Phase 1 Trial, A Non-Invasive Biomarker of Target Engagement Keystone Symposium - New Frontiers in Understanding Tumor Metabolism Graviton Love4
Oncology 11/2015 A First in Human Study of the First in Class Fatty Acid Synthase (FASN) Inhibitor TVB-2640. Results of Dose Escalation in Mono and Combination and Evidence of Preliminary Activity EORTC-NCI-AACR International Conference Graviton Love4